Search hospitals > Nebraska > Omaha
Novartis Investigative Site
Claim this profileOmaha, Nebraska 68134
Global Leader in Flu
Global Leader in Influenza
Conducts research for Chronic Obstructive Pulmonary Disease
Conducts research for COVID-19
Conducts research for Obstructive Lung Diseases
234 reported clinical trials
3 medical researchers
Summary
Novartis Investigative Site is a medical facility located in Omaha, Nebraska. This center is recognized for care of Flu, Influenza, Chronic Obstructive Pulmonary Disease, COVID-19, Obstructive Lung Diseases and other specialties. Novartis Investigative Site is involved with conducting 234 clinical trials across 158 conditions. There are 3 research doctors associated with this hospital, such as Brandon Essink, MD, Frederick Raiser, DO, and John Hallgren.Area of expertise
1Flu
Global Leaderestrogen
ER
2Influenza
Global LeaderTop PIs
Brandon Essink, MDMeridian Clinical Research1 year of reported clinical research
Studies Flu
Studies Viral Diseases
3 reported clinical trials
4 drugs studied
Frederick Raiser, DOVelocity Clinical Research1 year of reported clinical research
Studies COVID-19
Studies Coronavirus
2 reported clinical trials
4 drugs studied
John HallgrenNovartis Investigative Site4 years of reported clinical research
Studies Cardiovascular Disease
1 reported clinical trial
1 drug studied
Clinical Trials running at Novartis Investigative Site
Flu
Cardiovascular Disease
Hidradenitis Suppurativa
Flu Shot
Zika
Zika Virus
Atherosclerosis
Type 2 Diabetes
High Blood Sugar
High Blood Pressure
modRNA Vaccine
for Flu
This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza vaccine in healthy adults 18 years of age and older.
Recruiting2 awards Phase 31 criteria
Flu Vaccine
for Adults
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV- standard dose (SD), QIV- high dose (HD) [adults ≥ 65 years of age only], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.
Recruiting1 award Phase 1 & 2
H2N3 Influenza Vaccine
for Flu
This Phase 1, randomized, observer-blind, dose-ranging clinical study is evaluating 6 different formulations of MF59-adjuvanted and non-adjuvanted H2N3 influenza vaccine. Approximately 600 healthy adult subjects are to be randomized into 1 of 6 possible treatment groups with 100 subjects per group, stratified by age group (born after or before 1968). Each subject will receive an influenza vaccine injection on Day 1 and Day 22. Subjects will be followed up for approximately 12 months after the second vaccine injection. The primary immunogenicity analysis is based on the Day 1, Day 8, Day 22, Day 29, and Day 43 serology data. The primary safety analysis is based on solicited local and systemic adverse events (AEs) reported within 10 days after each vaccination, unsolicited AEs reported within 3 weeks after each vaccination, and serious AEs (SAEs), medically attended AEs (MAAEs), AEs leading to withdrawal from the study, and AEs of special interest (AESIs) reported throughout the study.
Recruiting1 award Phase 14 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Novartis Investigative Site?
Novartis Investigative Site is a medical facility located in Omaha, Nebraska. This center is recognized for care of Flu, Influenza, Chronic Obstructive Pulmonary Disease, COVID-19, Obstructive Lung Diseases and other specialties. Novartis Investigative Site is involved with conducting 234 clinical trials across 158 conditions. There are 3 research doctors associated with this hospital, such as Brandon Essink, MD, Frederick Raiser, DO, and John Hallgren.